VACCINES MARKET ANALYSIS

Vaccines Market, By Type (Monovalent Vaccines , Multitvalent Vaccines), By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other Vaccine Technologies), By Disease Indication (Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, RSV, Other Disease Indications), By Route of Administration (Intramuscular, Subcutaneous, Oral, Intranasal), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In June 2024, Sanofi and Cape Town-based Biovac announced a partnership to locally manufacture inactivated polio vaccines (IPV) in Africa. This agreement will enable Biovac to produce IPV for over 40 African countries, making it the continent’s first IPV producer. The initiative supports the Africa Centers for Disease Control and Prevention’s goal of having 60% of vaccines produced locally in Africa by 2040.
In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to jointly market a COVID-19 vaccine and develop novel combination vaccines for COVID-19 and influenza. This partnership allows both companies to combine their expertise and resources to deliver innovative vaccine solutions, strengthening their position in the competitive vaccine development and distribution market.
In January 2024, The Serum Institute of India Pvt. Ltd (SII), the world’s largest vaccine manufacturer, is joining CEPI's network of vaccine producers in the Global South. This partnership aims to enhance rapid and equitable vaccine responses to future health crises.
In April 2023, Pfizer revealed phase 3 trial results for its RSV vaccine, showing it was 67% more effective in preventing infections with two related symptoms and 86% effective against severe disease. This approval will mark Pfizer's entry as the first company in the RSV vaccine market.